The purchase will expand the expertise of Symrise in the efficacy testing of cosmetic ingredients and open new opportunities for collaboration with partners from scientific institutions. It will also increase the go-to-market speed for novel active ingredients.
“Cutech constitutes the perfect fit for Symrise’s cosmetic ingredients division. The highly specific R&D and biotechnology capabilities of Cutech optimally complement the research expertise of Symrise,” said Dr. Gerhard Schmaus, head of the global innovation cosmetic ingredients division at Symrise.
As a biotech company founded in 2002, Cutech specializes in unique pre-clinical screening services based on innovative proprietary ex vivo skin, sebaceous gland and hair models. The company also contributes IP on natural ingredients, such as micro algae, to supplement the Symrise portfolio.